OBJECTIVE -Endothelial markers endothelin 1 (ET-1) and von Willebrand factor (vWF) were assessed in patients with type 2 diabetes and dyslipidemia and in patients with hypercholesterolemia.RESEARCH DESIGN AND METHODS -In this case-control study, plasma ET-1 and vWF levels were measured by enzyme-linked immunosorbent assay in 35 normoalbuminuric type 2 diabetic patients with dyslipidemia (56 ± 5 years), in 21 nondiabetic patients with hypercholesterolemia (52 ± 7 years), and in 19 healthy control subjects (45 ± 4 years).All of the individuals were normotensive and nonsmokers. Urinary albumin was measured by immunoturbidimetry.RESULTS -ET-1 levels were higher (P Ͻ 0.0001) in type 2 diabetic dyslipidemic patients (1.62 ± 0.73 pg/ml) than in both nondiabetic hypercholesterolemic patients (0.91 ± 0.73 pg/ml) and control subjects (0.69 ± 0.25 pg/ml). vWF levels were significantly increased (P = 0.02) in type 2 diabetic (185.49 ± 72.1%) and hypercholesterolemic (163.29 ± 50.7%) patients compared with control subjects (129.70 ± 35.2%). In the multiple linear regression analysis, ET-1 was significantly associated (adjusted r 2 = 0.42) with serum triglyceride levels (P Ͻ 0.001), age (P Ͻ 0.01), insulin sensitivity index (P Ͻ 0.02), and albuminuria levels (P Ͻ 0.04). vWF levels were associated (adjusted r 2 = 0.22) with albuminuria (P Ͻ 0.001), fibrinogen levels (P Ͻ 0.02), and BMI (P Ͻ 0.03).CONCLUSIONS -Compared with hypercholesterolemic patients, type 2 diabetic patients with dyslipidemia have increased levels of ET-1 and vWF, which may indicate more pronounced endothelial injury. These findings appear to be related to components of the insulin resistance syndrome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.